How to Buy suvenphar Shares on Fincept?
You can buy Suven Pharmaceuticals Limited shares on Different Brokers & Banks by creating an account and completing KYC verification online.
NSE: Suven Pharmaceuticals Limited Share Price Today, Share Analysis, Latest Updates & Insights | Fincept
Stay informed with the latest announcements for Suvenphar, including updates on board meetings and corporate actions.
Suven Pharmaceuticals Limited - https://suvenpharm.com
Suven Pharmaceuticals Limited operates as a bio-pharmaceutical company in India, the United States, Europe, and internationally. It develops, manufactures, and sells new chemical entity-based intermediates, active pharmaceutical ingredients, specialty chemicals, and formulated drugs under contract research and manufacturing services for pharmaceutical, biotechnology, and chemical companies. The company was founded in 1989 and is based in Hyderabad, India. Suven Pharmaceuticals Limited is a subsidiary of Berhyanda Limited.
Suven Pharmaceuticals Limited Share Price Today
1,003.40
OPEN
1,056.05
HIGH
1,000.10
LOW
1,037.90
CLOSE
174 K
VOLUME
29,183 Cr
Market Cap
269035
Average Volume
Healthcare
Sector
NSI
Exchange
Suven Pharmaceuticals Limited Share Analysis & 2025 Insights
Investor Presentations
| Date | Description | Download |
|---|
SIP
Lumpsum
Invested Amount: ₹
Estimated Returns: ₹
Total Value: ₹
NSE: SUVENPHAR Stock Actions
Company |
Symbol |
ISIN |
Subject |
Ex Date |
Face Value |
Broadcast Date |
|---|---|---|---|---|---|---|
Suven Pharmaceuticals Limited |
SUVENPHAR |
INE03QK01018 |
Annual General Meeting |
06 Aug 2024 |
1 |
N/A |
Suven Pharmaceuticals Limited |
SUVENPHAR |
INE03QK01018 |
Annual General Meeting |
12 Dec 2023 |
1 |
N/A |
Suven Pharmaceuticals Limited |
SUVENPHAR |
INE03QK01018 |
Interim Dividend - Re 1 Per Share/Special Dividend- Rs 5 Per Share |
09 Sep 2022 |
1 |
N/A |
Suven Pharmaceuticals Limited |
SUVENPHAR |
INE03QK01018 |
Annual General Meeting |
11 Aug 2022 |
1 |
N/A |
Suven Pharmaceuticals Limited |
SUVENPHAR |
INE03QK01018 |
Interim Dividend - Re 1 Per Share/Special Dividend - Re 1 Per Share |
13 May 2022 |
1 |
N/A |
NSE: SUVENPHAR Recent Announcements
Symbol |
Date |
Description |
Industry |
|---|---|---|---|
SUVENPHAR |
01 Jan 2025, 17:31:34 |
General Updates |
N/A |
SUVENPHAR |
28 Dec 2024, 15:34:13 |
Board Meeting Intimation |
N/A |
SUVENPHAR |
28 Dec 2024, 15:29:17 |
Trading Window-XBRL |
N/A |
SUVENPHAR |
27 Dec 2024, 20:15:26 |
Trading Window |
N/A |
SUVENPHAR |
21 Dec 2024, 15:28:24 |
General Updates |
N/A |
NSE: SUVENPHAR Corporate Governance
Name |
Symbol |
Timestamp |
Submission Date |
XBRL Document |
|---|---|---|---|---|
Suven Pharmaceuticals Limited |
SUVENPHAR |
18 Oct 2024, 17:57:00 |
18 Oct 2024, 17:57:00 |
|
Suven Pharmaceuticals Limited |
SUVENPHAR |
19 Jul 2024, 19:06:00 |
19 Jul 2024, 19:06:00 |
|
Suven Pharmaceuticals Limited |
SUVENPHAR |
17 Apr 2024, 18:30:00 |
17 Apr 2024, 19:00:00 |
|
Suven Pharmaceuticals Limited |
SUVENPHAR |
18 Jan 2024, 19:00:00 |
18 Jan 2024, 19:30:00 |
|
Suven Pharmaceuticals Limited |
SUVENPHAR |
21 Oct 2023, 11:45:00 |
05 Feb 2025, 19:41:41 |
NSE: SUVENPHAR Detailed Governance
Category |
Date of Birth |
Date of Initial Appointment |
DIN |
Director Name |
Status |
|---|---|---|---|---|---|
Chairperson & Executive Director |
10 Jun 1967 |
20 Sep 2024 |
08559495 |
VIVEK SHARMA |
Active |
Executive Director-MD |
20 Feb 1974 |
29 Sep 2023 |
07267366 |
VENKATA NAGA KALI VARA PRASADA RAJU VETUKURI |
Active |
Non-Executive Director |
22 Mar 1980 |
29 Sep 2023 |
08206620 |
PANKAJ PATWARI |
Active |
Non-Executive Director |
29 Jan 1976 |
09 Nov 2023 |
00291675 |
SHWETA JALAN |
Active |
Independent Director |
27 Feb 1958 |
29 Sep 2023 |
01518137 |
MATANGI GOWRISHANKAR |
Active |
NSE: SUVENPHAR Board Meetings
Purpose |
Symbol |
Industry |
ISIN |
Name |
Time |
|---|---|---|---|---|---|
SUVEN PHARMACEUTICALS LIMITED has informed the Exchange about Board Meeting to be held on 12-Nov-2024 to inter-alia consider and approve the Unaudited Financial results of the Company for the Half Yearly ended September 2024 . |
SUVENPHAR |
N/A |
INE03QK01018 |
Suven Pharmaceuticals Limited |
27 Sep 2024, 11:38:07 |
Financial Results |
SUVENPHAR |
N/A |
INE03QK01018 |
Suven Pharmaceuticals Limited |
02 Aug 2024, 18:53:14 |
SUVEN PHARMACEUTICALS LIMITED has informed the Exchange about Board Meeting to be held on 30-May-2024 to inter-alia consider and approve the Audited Financial results of the Company for the Yearly ended March 2024 . |
SUVENPHAR |
N/A |
INE03QK01018 |
Suven Pharmaceuticals Limited |
21 May 2024, 13:10:14 |
SUVEN PHARMACEUTICALS LIMITED has informed the Exchange about Board Meeting to be held on 27-May-2024 to inter-alia consider and approve the Audited Financial results of the Company for the Yearly ended March 2024 . |
SUVENPHAR |
N/A |
INE03QK01018 |
Suven Pharmaceuticals Limited |
20 May 2024, 17:36:37 |
Financial Results |
SUVENPHAR |
N/A |
INE03QK01018 |
Suven Pharmaceuticals Limited |
29 Jan 2024, 17:11:15 |
NSE: SUVENPHAR Event Calendar
Purpose |
Symbol |
Industry |
ISIN |
Name |
Time |
Description |
|---|---|---|---|---|---|---|
Financial Results |
SUVENPHAR |
- |
INE03QK01018 |
Suven Pharmaceuticals Limited |
27 Dec 2024, 00:00:00 |
To consider and approve the financial results for the period ending December 31, 2024 |
Financial Results |
SUVENPHAR |
- |
INE03QK01018 |
Suven Pharmaceuticals Limited |
26 Sep 2024, 00:00:00 |
To consider and approve the financial results for the period ended September 30, 2024 |
Financial Results |
SUVENPHAR |
- |
INE03QK01018 |
Suven Pharmaceuticals Limited |
02 Aug 2024, 00:00:00 |
To consider and approve the financial results for the period ended Jun 30, 2024 |
Financial Results |
SUVENPHAR |
- |
INE03QK01018 |
Suven Pharmaceuticals Limited |
20 May 2024, 00:00:00 |
To consider and approve the financial results for the period ended March 31, 2024 |
Financial Results |
SUVENPHAR |
- |
INE03QK01018 |
Suven Pharmaceuticals Limited |
21 May 2024, 00:00:00 |
SUVENPHAR : 30-May-2024 : The Company has informed the Exchange that a Board meeting to be held on May 27, 2024 has been re-scheduled. Further, the Company has informed the Exchange that the meeting of the Board of Directors of the Company will be held on May 30, 2024, To consider and approve the financial results for the period ended March 31, 2024 |
NSE: SUVENPHAR Balance Sheet Data In (Cr)
| date | period_type | Ordinary Shares Number | Share Issued | Net Debt | Total Debt | Tangible Book Value | Invested Capital | Working Capital | Net Tangible Assets | Capital Lease Obligations | Common Stock Equity | Total Capitalization | Total Equity Gross Minority Interest | Minority Interest | Stockholders Equity | Other Equity Interest | Retained Earnings | Additional Paid In Capital | Capital Stock | Common Stock | Total Liabilities Net Minority Interest | Total Non Current Liabilities Net Minority Interest | Other Non Current Liabilities | Non Current Pension And Other Postretirement Benefit Plans | Non Current Deferred Taxes Liabilities | Long Term Debt And Capital Lease Obligation | Long Term Capital Lease Obligation | Long Term Debt | Long Term Provisions | Current Liabilities | Other Current Liabilities | Current Debt And Capital Lease Obligation | Current Capital Lease Obligation | Current Debt | Pensionand Other Post Retirement Benefit Plans Current | Current Provisions | Payables | Other Payable | Dividends Payable | Total Tax Payable | Accounts Payable | Total Assets | Total Non Current Assets | Other Non Current Assets | Defined Pension Benefit | Non Current Prepaid Assets | Non Current Deferred Taxes Assets | Other Investments | Investmentin Financial Assets | Available For Sale Securities | Financial Assets Designatedas Fair Value Through Profitor Loss | Long Term Equity Investment | Investmentsin Associatesat Cost | Goodwill And Other Intangible Assets | Other Intangible Assets | Goodwill | Net PPE | Accumulated Depreciation | Gross PPE | Construction In Progress | Other Properties | Machinery Furniture Equipment | Buildings And Improvements | Land And Improvements | Properties | Current Assets | Other Current Assets | Restricted Cash | Prepaid Assets | Inventory | Other Inventories | Finished Goods | Work In Process | Raw Materials | Other Receivables | Taxes Receivable | Accounts Receivable | Allowance For Doubtful Accounts Receivable | Gross Accounts Receivable | Cash Cash Equivalents And Short Term Investments | Other Short Term Investments | Cash And Cash Equivalents | Cash Equivalents | Cash Financial | Assets Held For Sale Current |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-09-30T00:00:00 | quarterly | 254,564,956.00 | 254,564,956.00 | 0.00 | 394,600,000.00 | 17,068,000,000.00 | 19,874,100,000.00 | 9,295,100,000.00 | 17,068,000,000.00 | 303,900,000.00 | 19,783,400,000.00 | 19,854,800,000.00 | 20,284,200,000.00 | 500,800,000.00 | 19,783,400,000.00 | 19,528,800,000.00 | 0.00 | 0.00 | 254,600,000.00 | 254,600,000.00 | 4,771,400,000.00 | 2,390,000,000.00 | 0.00 | 0.00 | 859,300,000.00 | 306,600,000.00 | 235,200,000.00 | 71,400,000.00 | 23,100,000.00 | 2,381,400,000.00 | 89,000,000.00 | 88,000,000.00 | 68,700,000.00 | 19,300,000.00 | 0.00 | 171,300,000.00 | 781,000,000.00 | 0.00 | 0.00 | 128,200,000.00 | 652,800,000.00 | 25,055,600,000.00 | 13,379,100,000.00 | 106,300,000.00 | 0.00 | 0.00 | 73,800,000.00 | 0.00 | 1,420,200,000.00 | 1,420,200,000.00 | 0.00 | 0.00 | 0.00 | 2,715,400,000.00 | 577,800,000.00 | 2,137,600,000.00 | 8,927,600,000.00 | 0.00 | 8,927,600,000.00 | 2,408,200,000.00 | 6,519,400,000.00 | 0.00 | 0.00 | 0.00 | 0.00 | 11,676,500,000.00 | 588,600,000.00 | 0.00 | 0.00 | 2,154,800,000.00 | 0.00 | 0.00 | 0.00 | 0.00 | 17,000,000.00 | 0.00 | 1,839,500,000.00 | 0.00 | 0.00 | 6,729,800,000.00 | 6,361,600,000.00 | 368,200,000.00 | 0.00 | 0.00 | 346,800,000.00 |
| 2024-03-31T00:00:00 | quarterly | 254,564,956.00 | 254,564,956.00 | 0.00 | 649,964,000.00 | 19,887,377,000.00 | 20,892,387,000.00 | 11,562,906,000.00 | 19,887,377,000.00 | 264,211,000.00 | 20,506,634,000.00 | 20,506,634,000.00 | 20,506,635,000.00 | 0.00 | 20,506,634,000.00 | 19,945,000.00 | 17,651,179,000.00 | 1,095,738,000.00 | 254,565,000.00 | 254,565,000.00 | 2,034,230,000.00 | 965,273,000.00 | 1,000.00 | 105,004,000.00 | 647,912,000.00 | 212,356,000.00 | 212,356,000.00 | 0.00 | 105,004,000.00 | 1,068,957,000.00 | 65,086,000.00 | 437,608,000.00 | 51,855,000.00 | 385,753,000.00 | 47,437,000.00 | 47,437,000.00 | 511,939,000.00 | 78,183,000.00 | 10,182,000.00 | 0.00 | 423,574,000.00 | 22,540,865,000.00 | 9,909,002,000.00 | -3,000.00 | 2,049,000.00 | 93,720,000.00 | 0.00 | 0.00 | 1,305,819,000.00 | 1,399,539,000.00 | 1,305,819,000.00 | 0.00 | 0.00 | 619,257,000.00 | 16,674,000.00 | 602,583,000.00 | 7,888,085,000.00 | -2,521,267,000.00 | 10,409,352,000.00 | 1,810,039,000.00 | 937,083,000.00 | 5,260,532,000.00 | 2,251,234,000.00 | 150,464,000.00 | 0.00 | 12,631,863,000.00 | 1,000.00 | 32,677,000.00 | 168,786,000.00 | 2,311,956,000.00 | 44,251,000.00 | 628,387,000.00 | 1,006,244,000.00 | 633,074,000.00 | 66,993,000.00 | 503,591,000.00 | 1,336,592,000.00 | 0.00 | 1,336,592,000.00 | 8,211,267,000.00 | 7,738,955,000.00 | 472,312,000.00 | 50,000,000.00 | 422,312,000.00 | 0.00 |
| 2024-03-31T00:00:00 | annual | 254,564,956.00 | 254,564,956.00 | 0.00 | 649,964,000.00 | 19,887,377,000.00 | 20,892,387,000.00 | 11,562,906,000.00 | 19,887,377,000.00 | 264,211,000.00 | 20,506,634,000.00 | 20,506,634,000.00 | 20,506,635,000.00 | 0.00 | 20,506,634,000.00 | 19,945,000.00 | 17,651,179,000.00 | 1,095,738,000.00 | 254,565,000.00 | 254,565,000.00 | 2,034,230,000.00 | 965,273,000.00 | 1,000.00 | 105,004,000.00 | 647,912,000.00 | 212,356,000.00 | 212,356,000.00 | 0.00 | 105,004,000.00 | 1,068,957,000.00 | 65,086,000.00 | 437,608,000.00 | 51,855,000.00 | 385,753,000.00 | 47,437,000.00 | 47,437,000.00 | 511,939,000.00 | 78,183,000.00 | 10,182,000.00 | 0.00 | 423,574,000.00 | 22,540,865,000.00 | 9,909,002,000.00 | -3,000.00 | 2,049,000.00 | 93,720,000.00 | 0.00 | 0.00 | 1,305,819,000.00 | 1,399,539,000.00 | 1,305,819,000.00 | 0.00 | 0.00 | 619,257,000.00 | 16,674,000.00 | 602,583,000.00 | 7,888,085,000.00 | -2,521,267,000.00 | 10,409,352,000.00 | 1,810,039,000.00 | 937,083,000.00 | 5,260,532,000.00 | 2,251,234,000.00 | 150,464,000.00 | 0.00 | 12,631,863,000.00 | 1,000.00 | 32,677,000.00 | 168,786,000.00 | 2,311,956,000.00 | 44,251,000.00 | 628,387,000.00 | 1,006,244,000.00 | 633,074,000.00 | 66,993,000.00 | 503,591,000.00 | 1,336,592,000.00 | 0.00 | 1,336,592,000.00 | 8,211,267,000.00 | 7,738,955,000.00 | 472,312,000.00 | 50,000,000.00 | 422,312,000.00 | 0.00 |
| 2023-09-30T00:00:00 | quarterly | 254,564,956.00 | 254,564,956.00 | 0.00 | 507,868,000.00 | 18,733,827,000.00 | 19,845,369,000.00 | 10,566,902,000.00 | 18,733,827,000.00 | 16,537,000.00 | 19,354,038,000.00 | 19,354,038,000.00 | 19,354,038,000.00 | 0.00 | 19,354,038,000.00 | 19,099,473,000.00 | 0.00 | 0.00 | 254,565,000.00 | 254,565,000.00 | 1,843,696,000.00 | 719,911,000.00 | 0.00 | 0.00 | 619,061,000.00 | 8,678,000.00 | 8,678,000.00 | 0.00 | 92,172,000.00 | 1,123,785,000.00 | 49,081,000.00 | 499,190,000.00 | 7,859,000.00 | 491,331,000.00 | 0.00 | 50,968,000.00 | 429,924,000.00 | 0.00 | 0.00 | 3,985,000.00 | 425,939,000.00 | 21,197,734,000.00 | 9,507,047,000.00 | 34,960,000.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1,239,149,000.00 | 1,239,149,000.00 | 0.00 | 0.00 | 0.00 | 620,211,000.00 | 620,211,000.00 | 0.00 | 7,612,455,000.00 | 0.00 | 7,612,455,000.00 | 1,723,271,000.00 | 5,889,184,000.00 | 0.00 | 0.00 | 0.00 | 0.00 | 11,690,687,000.00 | 466,047,000.00 | 0.00 | 0.00 | 2,714,629,000.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2,657,000.00 | 0.00 | 1,368,987,000.00 | 0.00 | 0.00 | 7,138,367,000.00 | 6,562,600,000.00 | 575,767,000.00 | 0.00 | 0.00 | 0.00 |
| 2023-03-31T00:00:00 | quarterly | 254,564,956.00 | 254,564,956.00 | 43,592,000.00 | 703,408,000.00 | 16,729,940,000.00 | 18,043,463,000.00 | 8,522,799,000.00 | 16,729,940,000.00 | 11,788,000.00 | 17,351,843,000.00 | 17,397,485,000.00 | 17,351,843,000.00 | 0.00 | 17,351,843,000.00 | 17,097,278,000.00 | 14,651,606,000.00 | 1,095,738,000.00 | 254,565,000.00 | 254,565,000.00 | 2,305,595,000.00 | 717,936,000.00 | 0.00 | 82,950,000.00 | 582,346,000.00 | 52,640,000.00 | 6,998,000.00 | 45,642,000.00 | 0.00 | 1,587,659,000.00 | 21,450,000.00 | 650,768,000.00 | 4,790,000.00 | 645,978,000.00 | 39,461,000.00 | 0.00 | 867,780,000.00 | 153,353,000.00 | 10,572,000.00 | 2,939,000.00 | 700,916,000.00 | 19,657,438,000.00 | 9,546,980,000.00 | -4,000.00 | 0.00 | 59,119,000.00 | 0.00 | 705,000.00 | 1,170,967,000.00 | 1,230,085,000.00 | 1,170,967,000.00 | 0.00 | 0.00 | 621,903,000.00 | 19,320,000.00 | 602,583,000.00 | 7,694,770,000.00 | -2,100,975,000.00 | 9,795,745,000.00 | 1,683,405,000.00 | 680,789,000.00 | 5,080,791,000.00 | 2,200,296,000.00 | 150,464,000.00 | 0.00 | 10,110,458,000.00 | 3,000.00 | 32,112,000.00 | 335,620,000.00 | 3,128,104,000.00 | 40,437,000.00 | 991,354,000.00 | 1,134,832,000.00 | 961,481,000.00 | 17,626,000.00 | 650,222,000.00 | 1,109,393,000.00 | 0.00 | 1,109,393,000.00 | 4,837,378,000.00 | 4,189,350,000.00 | 648,028,000.00 | 50,000,000.00 | 598,027,000.00 | 0.00 |
| 2023-03-31T00:00:00 | annual | 254,564,956.00 | 254,564,956.00 | 43,592,000.00 | 703,408,000.00 | 16,729,940,000.00 | 18,043,463,000.00 | 8,522,799,000.00 | 16,729,940,000.00 | 11,788,000.00 | 17,351,843,000.00 | 17,397,485,000.00 | 17,351,843,000.00 | 0.00 | 17,351,843,000.00 | 17,097,278,000.00 | 14,651,606,000.00 | 1,095,738,000.00 | 254,565,000.00 | 254,565,000.00 | 2,305,595,000.00 | 717,936,000.00 | 0.00 | 82,950,000.00 | 582,346,000.00 | 52,640,000.00 | 6,998,000.00 | 45,642,000.00 | 0.00 | 1,587,659,000.00 | 21,450,000.00 | 650,768,000.00 | 4,790,000.00 | 645,978,000.00 | 39,461,000.00 | 0.00 | 867,780,000.00 | 153,353,000.00 | 10,572,000.00 | 2,939,000.00 | 700,916,000.00 | 19,657,438,000.00 | 9,546,980,000.00 | -4,000.00 | 0.00 | 59,119,000.00 | 0.00 | 705,000.00 | 1,170,967,000.00 | 1,230,085,000.00 | 1,170,967,000.00 | 0.00 | 0.00 | 621,903,000.00 | 19,320,000.00 | 602,583,000.00 | 7,694,770,000.00 | -2,100,975,000.00 | 9,795,745,000.00 | 1,683,405,000.00 | 680,789,000.00 | 5,080,791,000.00 | 2,200,296,000.00 | 150,464,000.00 | 0.00 | 10,110,458,000.00 | 3,000.00 | 32,112,000.00 | 335,620,000.00 | 3,128,104,000.00 | 40,437,000.00 | 991,354,000.00 | 1,134,832,000.00 | 961,481,000.00 | 17,626,000.00 | 650,222,000.00 | 1,109,393,000.00 | 0.00 | 1,109,393,000.00 | 4,837,378,000.00 | 4,189,350,000.00 | 648,028,000.00 | 50,000,000.00 | 598,027,000.00 | 0.00 |
| 2022-03-31T00:00:00 | annual | 254,564,956.00 | 254,564,956.00 | 510,096,000.00 | 971,272,000.00 | 15,249,439,000.00 | 16,227,537,000.00 | 9,176,380,000.00 | 15,249,439,000.00 | 15,538,000.00 | 15,271,803,000.00 | 15,556,207,000.00 | 15,271,804,000.00 | 0.00 | 15,271,803,000.00 | 15,017,239,000.00 | 12,727,086,000.00 | 1,095,738,000.00 | 254,565,000.00 | 254,565,000.00 | 3,024,069,000.00 | 921,129,000.00 | 0.00 | 88,945,000.00 | 543,151,000.00 | 289,033,000.00 | 4,629,000.00 | 284,404,000.00 | 88,945,000.00 | 2,102,940,000.00 | 20,992,000.00 | 682,239,000.00 | 10,909,000.00 | 671,330,000.00 | 40,753,000.00 | 0.00 | 1,116,698,000.00 | 15,348,000.00 | 5,923,000.00 | 36,422,000.00 | 1,059,005,000.00 | 18,295,873,000.00 | 7,016,553,000.00 | -1,000.00 | 0.00 | 53,916,000.00 | 0.00 | 705,000.00 | 1,170,262,000.00 | 1,297,926,000.00 | 1,170,262,000.00 | 0.00 | 0.00 | 22,364,000.00 | 22,364,000.00 | 0.00 | 5,695,569,000.00 | -1,578,446,000.00 | 7,274,015,000.00 | 375,994,000.00 | 474,065,000.00 | 4,460,046,000.00 | 1,813,446,000.00 | 150,464,000.00 | 0.00 | 11,279,320,000.00 | 14,563,000.00 | 27,420,000.00 | 299,664,000.00 | 2,834,173,000.00 | 25,525,000.00 | 599,239,000.00 | 1,317,505,000.00 | 891,904,000.00 | 14,757,000.00 | 467,158,000.00 | 2,363,723,000.00 | 0.00 | 2,363,723,000.00 | 5,257,862,000.00 | 4,812,224,000.00 | 445,638,000.00 | 0.00 | 0.00 | 0.00 |
| 2021-03-31T00:00:00 | annual | 254,564,956.00 | 254,564,956.00 | 1,340,462,000.00 | 1,430,357,000.00 | 11,782,179,000.00 | 13,220,368,000.00 | 3,450,372,000.00 | 11,782,179,000.00 | 18,072,000.00 | 11,808,083,000.00 | 12,163,992,000.00 | 11,807,983,000.00 | 0.00 | 11,808,083,000.00 | 11,553,518,000.00 | 9,364,926,000.00 | 1,095,738,000.00 | 254,565,000.00 | 254,565,000.00 | 2,936,668,000.00 | 739,188,000.00 | 100,000.00 | 66,460,000.00 | 309,329,000.00 | 363,299,000.00 | 7,390,000.00 | 355,909,000.00 | 66,460,000.00 | 2,197,480,000.00 | 22,564,000.00 | 1,067,058,000.00 | 10,682,000.00 | 1,056,376,000.00 | 26,072,000.00 | 0.00 | 932,323,000.00 | 98,749,000.00 | 4,261,000.00 | 0.00 | 829,313,000.00 | 14,744,651,000.00 | 9,096,799,000.00 | -1,000.00 | 0.00 | 107,855,000.00 | 0.00 | 705,000.00 | 3,611,236,000.00 | 47,934,000.00 | 3,611,236,000.00 | 3,611,235,000.00 | 3,611,235,000.00 | 25,904,000.00 | 25,904,000.00 | 0.00 | 5,348,896,000.00 | -1,262,247,000.00 | 6,611,143,000.00 | 961,491,000.00 | 449,691,000.00 | 3,638,076,000.00 | 1,411,421,000.00 | 150,464,000.00 | 0.00 | 5,647,852,000.00 | 153,000.00 | 24,710,000.00 | 169,741,000.00 | 2,010,804,000.00 | 30,023,000.00 | 331,217,000.00 | 982,006,000.00 | 667,558,000.00 | 58,577,000.00 | 482,285,000.00 | 1,023,821,000.00 | 0.00 | 0.00 | 1,877,761,000.00 | 1,805,938,000.00 | 71,823,000.00 | 0.00 | 71,822,000.00 | 0.00 |
| 2020-03-31T00:00:00 | annual | 0.00 | 0.00 | 1,735,952,000.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 100,000.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 83,146,000.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 25,165,000.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 705,000.00 | 0.00 | 0.00 | 0.00 | 3,073,876,000.00 | 3,073,876,000.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 116,953,000.00 | 0.00 |
NSE: SUVENPHAR Cash Flow Data In (Cr)
| date | period_type | Free Cash Flow | Capital Expenditure | End Cash Position | Other Cash Adjustment Outside Changein Cash | Beginning Cash Position | Effect Of Exchange Rate Changes | Changes In Cash | Financing Cash Flow | Net Other Financing Charges | Interest Paid Cff | Cash Dividends Paid | Common Stock Dividend Paid | Net Issuance Payments Of Debt | Net Short Term Debt Issuance | Net Long Term Debt Issuance | Investing Cash Flow | Net Other Investing Changes | Interest Received Cfi | Net Investment Purchase And Sale | Sale Of Investment | Purchase Of Investment | Net Business Purchase And Sale | Sale Of Business | Net PPE Purchase And Sale | Sale Of PPE | Purchase Of PPE | Operating Cash Flow | Taxes Refund Paid | Change In Working Capital | Change In Other Current Liabilities | Change In Other Current Assets | Change In Payable | Change In Inventory | Change In Receivables | Other Non Cash Items | Stock Based Compensation | Depreciation And Amortization | Amortization Cash Flow | Depreciation | Gain Loss On Investment Securities | Net Foreign Currency Exchange Gain Loss | Gain Loss On Sale Of PPE | Net Income From Continuing Operations |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-03-31T00:00:00 | annual | 3,066,962,000.00 | -517,869,000.00 | 472,312,000.00 | -1,000.00 | 648,028,000.00 | 9,000.00 | -175,724,000.00 | -138,023,000.00 | 0.00 | -74,511,000.00 | 0.00 | 0.00 | -315,935,000.00 | -270,443,000.00 | -45,492,000.00 | -3,622,532,000.00 | 422,000.00 | 19,348,000.00 | -3,124,433,000.00 | 11,100,000.00 | -3,135,533,000.00 | 0.00 | 0.00 | -517,869,000.00 | 0.00 | -517,869,000.00 | 3,584,831,000.00 | -1,099,507,000.00 | 474,118,000.00 | 25,484,000.00 | 116,265,000.00 | -281,738,000.00 | 816,149,000.00 | -228,023,000.00 | 55,163,000.00 | 19,662,000.00 | 518,059,000.00 | 0.00 | 518,059,000.00 | -449,105,000.00 | 6,641,000.00 | 675,000.00 | 4,056,716,000.00 |
| 2023-03-31T00:00:00 | annual | 1,712,836,000.00 | -2,859,122,000.00 | 648,028,000.00 | 0.00 | 445,638,000.00 | 0.00 | 202,390,000.00 | -2,419,512,000.00 | 1,000.00 | -115,563,000.00 | -2,036,520,000.00 | -2,036,520,000.00 | -263,680,000.00 | -26,105,000.00 | -237,575,000.00 | -1,950,056,000.00 | 5,521,000.00 | 58,316,000.00 | 844,509,000.00 | 844,553,000.00 | -44,000.00 | 0.00 | 0.00 | -2,858,402,000.00 | 720,000.00 | -2,859,122,000.00 | 4,571,958,000.00 | -1,457,605,000.00 | 57,684,000.00 | -166,459,000.00 | -358,556,000.00 | -357,986,000.00 | -293,932,000.00 | 1,244,652,000.00 | 57,247,000.00 | 0.00 | 464,599,000.00 | 4,009,000.00 | 464,599,000.00 | -156,870,000.00 | 9,542,000.00 | 65,000.00 | 5,597,298,000.00 |
| 2022-03-31T00:00:00 | annual | 2,548,135,000.00 | -751,867,000.00 | 445,638,000.00 | 0.00 | 71,822,000.00 | 4,000.00 | 373,812,000.00 | -1,564,807,000.00 | 926,000.00 | -62,310,000.00 | -1,018,260,000.00 | -1,018,260,000.00 | -481,704,000.00 | -385,656,000.00 | -96,048,000.00 | -1,361,383,000.00 | -48,439,000.00 | 686,000.00 | -3,002,743,000.00 | 2,440,974,000.00 | -3,002,743,000.00 | 2,440,974,000.00 | 2,440,974,000.00 | -751,861,000.00 | 6,000.00 | -751,867,000.00 | 3,300,002,000.00 | -1,842,573,000.00 | -1,939,661,000.00 | 91,226,000.00 | -105,644,000.00 | 232,035,000.00 | -823,369,000.00 | -1,360,880,000.00 | 61,624,000.00 | 0.00 | 382,550,000.00 | 3,910,000.00 | 378,640,000.00 | -82,031,000.00 | 44,201,000.00 | -6,000.00 | 6,675,898,000.00 |
| 2021-03-31T00:00:00 | annual | 2,717,005,000.00 | -1,108,460,000.00 | 71,822,000.00 | 3,000.00 | 116,953,000.00 | 3,000.00 | -45,134,000.00 | -756,617,000.00 | 2,520,000.00 | -89,236,000.00 | -254,565,000.00 | -254,565,000.00 | -424,248,000.00 | 123,017,000.00 | -547,265,000.00 | -3,113,982,000.00 | -27,000.00 | 0.00 | -2,005,831,000.00 | 0.00 | -2,005,831,000.00 | 0.00 | 0.00 | -1,108,124,000.00 | 336,000.00 | -1,108,460,000.00 | 3,825,465,000.00 | -1,094,358,000.00 | -121,731,000.00 | 49,105,000.00 | -134,850,000.00 | 119,452,000.00 | -262,082,000.00 | 133,608,000.00 | 88,758,000.00 | 0.00 | 312,207,000.00 | 3,851,000.00 | 308,356,000.00 | -33,277,000.00 | -9,756,000.00 | -336,000.00 | 4,676,741,000.00 |
| 2020-03-31T00:00:00 | annual | 0.00 | 0.00 | 0.00 | 1,000.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2,767,000.00 | 0.00 | -767,229,000.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 3,606,000.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
NSE: SUVENPHAR Income Statement Data In (Cr)
| date | period_type | Tax Effect Of Unusual Items | Tax Rate For Calcs | Normalized EBITDA | Total Unusual Items | Total Unusual Items Excluding Goodwill | Net Income From Continuing Operation Net Minority Interest | Reconciled Depreciation | Reconciled Cost Of Revenue | EBITDA | EBIT | Net Interest Income | Interest Expense | Interest Income | Normalized Income | Net Income From Continuing And Discontinued Operation | Total Expenses | Rent Expense Supplemental | Diluted Average Shares | Basic Average Shares | Diluted EPS | Basic EPS | Diluted NI Availto Com Stockholders | Net Income Common Stockholders | Otherunder Preferred Stock Dividend | Net Income | Net Income Including Noncontrolling Interests | Net Income Continuous Operations | Tax Provision | Pretax Income | Other Non Operating Income Expenses | Special Income Charges | Other Special Charges | Restructuring And Mergern Acquisition | Net Non Operating Interest Income Expense | Total Other Finance Cost | Interest Expense Non Operating | Interest Income Non Operating | Operating Income | Operating Expense | Other Operating Expenses | Depreciation And Amortization In Income Statement | Amortization | Depreciation Income Statement | Research And Development | Selling General And Administration | Selling And Marketing Expense | General And Administrative Expense | Rent And Landing Fees | Gross Profit | Cost Of Revenue | Total Revenue | Operating Revenue |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-03-31T00:00:00 | annual | 12.27 | 0.00 | 420.41 | 47.21 | 47.21 | 300.28 | 51.81 | 448.51 | 467.63 | 413.12 | -5.44 | 7.45 | 2.02 | 265.33 | 300.28 | 681.06 | 0.97 | 25.46 | 25.46 | 0.00 | 0.00 | 300.28 | 300.28 | 0.00 | 300.28 | 300.28 | 300.28 | 105.39 | 405.67 | 0.99 | 2.30 | -5.53 | 3.22 | -5.44 | 0.00 | 7.45 | 2.02 | 354.78 | 232.55 | 27.14 | 54.50 | 0.41 | 54.09 | 0.00 | 29.52 | 10.35 | 19.17 | 0.97 | 587.34 | 448.51 | 1,035.85 | 1,035.85 |
| 2023-03-31T00:00:00 | annual | 4.78 | 0.00 | 602.51 | 18.01 | 18.01 | 411.29 | 46.46 | 586.19 | 620.53 | 572.54 | -6.98 | 12.81 | 5.83 | 398.05 | 411.29 | 804.81 | 0.00 | 25.46 | 25.46 | 0.00 | 0.00 | 411.29 | 411.29 | 0.00 | 411.29 | 411.29 | 411.29 | 148.44 | 559.73 | 0.96 | 2.33 | -2.33 | 0.00 | -6.98 | 7.37 | 12.81 | 5.83 | 526.30 | 218.61 | 25.03 | 47.99 | 0.40 | 47.59 | 8.59 | 36.57 | 17.64 | 18.93 | 0.00 | 744.92 | 586.19 | 1,331.11 | 1,331.11 |
| 2022-03-31T00:00:00 | annual | 23.77 | 0.00 | 638.70 | 74.22 | 74.22 | 453.80 | 38.26 | 572.29 | 712.92 | 673.82 | -8.46 | 6.23 | 0.07 | 403.35 | 453.80 | 763.81 | 0.01 | 25.46 | 25.46 | 0.00 | 0.00 | 453.80 | 453.80 | 0.00 | 453.80 | 453.80 | 453.80 | 213.79 | 667.59 | 1.10 | -0.20 | 0.20 | 0.00 | -8.46 | 2.30 | 6.23 | 0.07 | 543.20 | 191.52 | 17.92 | 39.10 | 0.39 | 38.71 | 10.35 | 36.62 | 19.80 | 16.82 | 0.01 | 734.72 | 572.29 | 1,307.01 | 1,307.01 |
| 2021-03-31T00:00:00 | annual | 0.76 | 0.00 | 505.09 | 3.36 | 3.36 | 362.34 | 31.22 | 435.73 | 508.45 | 476.82 | -11.40 | 9.14 | 0.27 | 359.74 | 362.34 | 584.10 | 0.35 | 25.46 | 25.46 | 0.00 | 0.00 | 362.34 | 362.34 | 0.00 | 362.34 | 362.34 | 362.34 | 105.33 | 467.67 | 1.05 | 0.03 | -0.03 | 0.00 | -11.40 | 2.52 | 9.14 | 0.27 | 411.37 | 148.37 | 16.77 | 31.64 | 0.39 | 31.25 | 11.06 | 26.58 | 10.53 | 16.05 | 0.35 | 559.73 | 435.73 | 995.46 | 995.46 |
| 2020-03-31T00:00:00 | annual | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 3.15 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 14.13 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
FII & DII Data (In Cr)
| Date | FII Gross Purchase | FII Gross Sales | FII Net Purchase / Sales | DII Gross Purchase | DII Gross Sales | DII Net Purchase / Sales |
|---|---|---|---|---|---|---|
| 2025-02-03 | 12,505.92 | 16,464.29 | -3,958.37 | 19,319.48 | 16,611.25 | 2,708.23 |
| 2025-01-30 | 10,513.63 | 15,096.58 | -4,582.95 | 13,934.35 | 11,768.46 | 2,165.89 |
| 2025-01-29 | 7,644.40 | 10,230.83 | -2,586.43 | 12,871.38 | 11,078.67 | 1,792.71 |
| 2025-01-27 | 9,488.57 | 14,504.03 | -5,015.46 | 16,503.43 | 9,861.28 | 6,642.15 |
| 2025-01-24 | 11,230.47 | 13,988.96 | -2,758.49 | 12,835.41 | 10,433.10 | 2,402.31 |
| 2025-01-23 | 13,316.55 | 18,779.07 | -5,462.52 | 14,412.73 | 10,700.18 | 3,712.55 |
| 2025-01-22 | 12,936.64 | 16,962.89 | -4,026.25 | 15,437.18 | 11,796.96 | 3,640.22 |
Piotroski F-Score
7/9
0
1
2
3
4
5
6
7
8
9
Key Metrics
EPS
9.48
P/E
120.928276
P/B
14.231094
Dividend Yield
N/A
Market Cap
29,183.33 Cr.
Face Value
80.556
Book Value
80.556
ROE
25.73%
EBITDA Growth
319.04 Cr.
Debt/Equity
3.17
Short Term
Subscribe to unlock this feature
Medium Term
Subscribe to unlock this feature
Long Term
Subscribe to unlock this feature
Yearly Stock Performance Heatmap
Latest Updates
Ashoka Buildcon Arm Signs Rs 1,391 Crore Pact With NHAI
Ashoka Buildcon Ltd. announced on Monday, via an exchange filing, that its wholly owned subsidiary, Ashoka Bowaichandi Guskara Road Pvt Ltd., has exec...
Budget 2025: Rahul Bajoria On Addressing Income Growth And Consumption Trends
"However, discretionary, high-value consumption is taking a step back due to income growth settling at high single digits." Over the past fe...
FPIs Stay Net Sellers, Sell Stocks Worth Rs 2,575 Crore
Foreign portfolio investors stayed net sellers for the second straight session on Monday and sold stocks worth approximately Rs 2,575.1 crore, accordi...
Budget 2025: AMFI Seeks Tax Policy Reforms To Drive Mutual Fund Investments In 15-Point Proposal
The Association of Mutual Funds of India on Monday released a 15-point proposal for Union Budget 2025-26 requesting changes in tax policies that are i...
Apple iPhone SE 4: Price To Features, 11 Things You Need To Know
iPhone 16e (Not iPhone SE 4): If recent reports are to be believed, Apple may discontinue the SE label and rename iPhone SE 4 as iPhone 16e. Most Affo...
Rupee Closed Weaker Against The US Dollar
The rupee weakened by five paise to close at 85.83 against the US dollar. The Indian rupee had declined to a fresh low against the US dollar during th...
Table Space Founder Amit Banerji Dies Of Heart Attack At Age Of 45
Amit Banerji, the founder, chairman and chief executive officer of managed workspace provider Table Space, died after suffering from a heart attack, r...
War Fatigue, Economic Breakdown Or Pro-West? Why Syria's Al-Sharaa Is Seen Soft On Israel
The strategic positions have been used by Israeli forces to carry out hundreds of strikes to destroy Syria's military infrastructure. In 2011, be...
Popular Questions
What is the Market Cap of suvenphar?
The market capitalization of Suven Pharmaceuticals Limited is ₹29,183 Cr as of 05 Feb 2025.
What are the PE and PB ratios of Suven Pharmaceuticals Limited?
The PE and PB ratios of Suven Pharmaceuticals Limited are Not Available and 14.231094 respectively as of 05 Feb 2025.
What is the 52 Week High of Suven Pharmaceuticals Limited?
The 52-week high of Suven Pharmaceuticals Limited is ₹1360 as of 05 Feb 2025.
What is the 52 Week Low of Suven Pharmaceuticals Limited?
The 52-week low of Suven Pharmaceuticals Limited is ₹585.2 as of 05 Feb 2025.
What are the earnings per share (EPS) for Suven Pharmaceuticals Limited?
The Earnings Per Share (EPS) of Suven Pharmaceuticals Limited is ₹9.48 as per the most recent quarterly results available on Fincept.
What is the ROE (Return on Equity) of Suven Pharmaceuticals Limited?
The Return on Equity (ROE) of Suven Pharmaceuticals Limited is 25.73% as per the most recent financial year data. Explore more on Fincept.